THE SHOCKING TRUTH ABOUT BMSN 90% of all start

New Post Public Reply Private Reply Replies (0) Message Board
DarkKnight83

[b]THE SHOCKING TRUTH ABOUT BMSN[/b]

90% of all start up companies biotech or not reports -O- income. Why would they have a revenue stream with no product? Once they have a marketable FDA

approved product then they can attract big pharma to buy them out! I never heard of any start-up penny stock company making millions of dollars in

revenue with no product! There will be a drastic change in PPS this July as FDA response is expected to come any day now that will initiate clinical

trials on humans.

Click on the link below to see why biotech companies need to dilute and what operating expenses they have?

http://www.dataev.com/it-experts-blog/bid/290...kimp-on-IT

Lawsuits? All BMSN Lawsuit have been [b]resolved[/b]! Case close! [b]Not[/b] wanted for federal questioning! Those lawsuit were meaningless! C'mon a

shell company that has no asset's nor product try's to cash in on BMSN!! Lawsuits happen all the time in every company! Not all claims are legit!

Look at StarCity capital LLC. with no [b]executives or employees[/b]! BWhahahahahahaha!! StarCity capital was just looking for a quick payday!! Its

equilavent to some sueing Mcdonalds for coffee that's too hot when they clearly ordered hot coffee!! lmao

http://investing.businessweek.com/research/st...=222502242

(Most Recent- Settled) Lawsuit Filed April 12, 2013

1. On January 2, 2013, Starcity exercised its right to convert $17,000 of its debt into

103,030,303 shares of BMSN (the “Conversion Notice”). The Conversion Notice took

advantage of extraordinarily low public market prices of BMSN common stock, as was Starcity’s

right under the STA. The next day, on January 3, 2013, Defendants, as they were required to do,

Between January 2, 2013 and February 27, 2013, Defendants, with the intent to

prefer their own personal and other stockholders’ stock positions ahead of Starcity’s lawful

stockholder position in BMSN, and to the knowing detriment of Starcity, used false promises and

deception to trick Starcity into surrendering its Starcity BMSN Stock Certificate based on the

false promise that such shares promptly would be transmitted electronically to Starcity’s

brokerage account via DWAC. For weeks after Starcity surrendered its Starcity BMSN Stock

Certificate, and while the price of BMSN stock was trading at similar very low prices,

Defendants continuously and falsely reassured Starcity that such DWACtransmission would be

made promptly. All the while, Defendants, and each of them, knew that Defendants intended to

construe the surrendering of such Starcity ...ons ahead of Starcity’s lawful

stockholder position in BMSN.

NOW THAT THESE Starcity FOOLS SOLD ALL THEIR BMSN TICKETS UP WE GO! THAT WAS THE LAST LAWSUIT WHICH HAS BEEN RESOLVED!!

Here are the other two which OLD and RESOLVED!!!

2. SETTLEMENT AGREEMENT

Parties: BIO-MATRIX SCIENTIFIC GROUP, INC. | 18 KTTV, LLC | BIO-MATRIX SCIENTIFIC GROUP, INC

Document Date: 3/12/2013

Industry: Medical Equipment and Supplies

Sector: Healthcare

Governing Law ennsylvania

3. SETTLEMENT AGREEMENT

Parties: ENTEST BIOMEDICAL, INC. | 18 KTTV, LLC | ENTEST BIOMEDICAL, INC

Document Date: 3/12/2013

Industry: Biotechnology and Drugs

Sector: Healthcare

Governing Law ennsylvania

10K spells out lawsuit resolution in section 11

THESE LAWSUITS ARE SO BORING AND IRREVELANT TO FDA APPROVAL! EVERY COMPANY WITH A LEGIMATE SERVICE OR PRODUCT IS EXPOSED TO LAWSUITS! BIG DEAL!!

CASE RESOLVED!! IN ADDITION THEY ARE ALL OLD! YAWN!!

CLICK ON THE LINK BELOW!! [b]ALL LAWSUIT ARE RESOLVED!![/b] LOOK ON THE BOTTOM 8 & 9!!

http://agreements.realdealdocs.com/Settlement-Agreement/

CLICK ON THE LINK BELOW TO FIND OUT WHY [b]DILUTION ISN"T ALWAYS A BAD THING[/b]!!

http://blog.seedrs.com/2013/06/14/why-dilutio...bad-thing/

http://www.dummies.com/how-to/content/new-pen...r-bad.html

[b]When new penny stock share issues are a good thing:[/b]

Legal battles: Smaller companies often find themselves in costly legal battles with much bigger players. For example, many tech companies must go to

court to enforce patents rights. To pay legal fees, companies may issue shares for general working capital purposes. When the company is on the right

side of a legal battle, it can be beneficial for them and shareholders to dilute in order to litigate.

The O/S is maxed out!! Dilution is over!

Here is an example of Oustanding shares and its impact!

Comparison of stocks - shares outstanding:

Intel (INTC) -      5.52 billion shares outstanding

Texas Instruments (TXN) -   1.24 billion shares outstanding (23% of Intel's # of shares)

Analog Devices (ADI) -      297.69 million shares outstanding (5% of Intel)

STMicroelectronics (STM) -      878.32 million shares outstanding (16% of Intel)

Advanced Micro Devices (AMD) -      672.13 million shares outstanding (12% of Intel)

Share stability and volatility:  A greater number of shares outstanding can also support the claim that a company has greater price stability, given

that it takes many more shares traded to create a significant percentage movement in the stock.  Contrary to this, the stock with a much lower number of

outstanding shares, like ADI above, representing only 5% of Intel's total, could be more vulnerable to price manipulation, requiring much fewer shares

to be traded up or down to move the stock price.

These BMSN Short Numbers are ridiculous

http://otcshortreport.com/index.php?index=BMSN

http://www.shortanalytics.com/getshortchart.php?tsymbol=BMSN

Good evening!! BMSN Crew!! BMSN has accomplished so much and has even been featured on NBC NEWS!! Know what you hold! There is plenty of DD out there!

These shares are more precious than gold right now! Treat it as such and enjoy the ride north!! We have a strong chance of hitting .007 today!!

http://www.nbcnews.com/id/51786808#.UZFZQIy9KSM

(Link is expired due to NBC featured news time frame)

Just because a company hired an outside source for more exposure doesn't make it a P&D scam!! eg. FB, FNMA

http://stockpromoters.com/view-stock-promotio...ceHolderyy

%24Footer1%24Image2.x=12&ctl00%24ContentPlaceHolderyy%24Footer1%24Image2.y=11

[i]

Get in now or miss the chance of a life time here!![/i]

Check out the technical chart analysis on BMSN! Clearly the charts are BULLISH!!

http://bullwarriorstocks.com/index.php/post/b...-6-14-2013

Oh Lawd look at this short volume!! I'm getting excited just thinking about the gains!! Please cover!

http://otcshortreport.com/index.php?index=BMSN

http://www.shortanalytics.com/getshortchart.php?tsymbol=BMSN

[b]Oncology Innovations[/b]

Some of biggest innovations have been in the field of oncology. The actress Angelina Jolie recently became the new face of breast cancer, after

announcing that she’d had a double-mastectomy upon discovering that she carried a gene that predicts about a 60 percent chance of developing the

disease.

Thanks to the advances in genetic screening, drug developers also now look for genetic mutations in tumors that can explain why they grow and

metastasize, and create drugs to specifically target that aspect of the disease.

Surely BMSN will save lives and eliminate the budden of a mastectomy! Breast cancer gene silicensing technology will do just that!!

Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program

http://finance.yahoo.com/news/bio-matrix-scie...00616.html

Lets just say that the FDA has 30days to respond which I highly doubt it would take that long cause they already have BMSN information filed on their

system! We should be hearing a verdict by Mid July the latest! But realisticly a response from FDA can come with 2-3 weeks considering that the response

is mailed!

"We are pleased with the responses that we have provided to the FDA and look forward to initiating our clinical trials," stated David Koos, Chairman and

CEO of Regen BioPharma. "Although it is possible that a second round of comments may be issued, we feel this process is extremely useful to creating a

clinical trial that is optimized for safety and detection of efficacy."

http://finance.yahoo.com/news/bio-matrix-scie...00616.html

This is not a 1 day flip! If your looking for that please exit left! There are plenty of BS pump and dumps out there! BMSN is a long term hold! The

clock for FDA response started JUNE 7, 2013! They have [b]30 days[/b] to respond back! So I say mid July - August

we should here a final verdict! I haven't seen any recent dilution! Just a lot of stupid trading and heavy manipulation!

For people who kept complaining about the time for [b]IND submission time frame[/b] please click the link below and your faith in BMSN will be restored!

On Feb 5, 2013 Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia!

http://www.ucdmc.ucdavis.edu/clinicaltrials/IND/step4.html

This link is proof that the application as MAIL rather Electronic submission! In the link it clearly states that the application must be mailed with 3

copies of the entire submission! Which mean Koos wasn't hiding information or delaying! It takes time to get the application processed, filed then

issued a reference number (IND#) Koos is operating with urgency not to please investors but to put BMSN on the right track to success!

Here the proof that [b]eliminates[/b] all doubt!! Copy and paste this text into a search engine! I used google! >>>>>>>investigational new drug (ind)

application process<<<<<<<

Next look for a PDF link from the FDA! It should be the Third box down! And the link should be something like this:

www.fda.gov/downloads/.../reportsmanualsforms/forms....

Ok now download the form yourself! Scroll to the bottom of the form! If clearly has signature panel boxes as well as the panel where a FDA official

would give the application an IND#!!!

IND# issuance is clearly not like buy a gallon a milk at the supermarket where a receipt is given immediately! The FDA submission process is very slow

for a reason! We are dealing with human life here! Have patience investors, sit back and accumulate those cheap shares while they are still here! [b]

Last major run we had only took 1 week to reach from sub-penny level to almost .02 cents!! That's how fast BMSN moves!! We will have our day in the sun!

[/b]

Now that we know for sure that we are operating in FISCAL year! Things will be very interesting in the next 30 days!! Not long before BMSN HemaXellerate

receives IND status!! My honest advice BUY and HOLD!! THESE PRICES ARE GIFTS!!

[b]FOURTH QUARTER [/b]STARTS IN JULY AND GUESS WHATS ON THE AGENDA!![b] BOOOMM [/b]TIME!!

Breast Cancer Technology NEWS was annouced in FEB. which mean BMSN business plan is in fiscal quarter NOT calender! This Breast Cancer news was FIRST

Press Release: Bio-Matrix Scientific Group Inc. – Tue, Feb 26, 2013 10:12 AM!!! Click on the link Below and do the math yourself! FDA news can arrive at

any moment! I can't believe people are confused on this issue! BMSN is not trying to confused investors! All the info is clearly laid out in black and

white!

WHY WOULD MMs ALLOW THE PPS TO RISE SO SUDDENLY THINK ABOUT IT!

http://finance.yahoo.com/news/bio-matrix-rege...30212.html

http://finance.yahoo.com/q/h?s=BMSN&t=201...2:12-04:00

FISCAL NOT CALENDER!!!

Upcoming Milestones

Response to FDA questions: Q3 2013

Initiate HemaXellerate trial: Q4 2013

Complete HemaXellerate trial: Q4 2014-Q2 2015

In license Min technology: Q2 2013

File IND on Min technology: Q4 2013

Initiate clinical trial on Min technology: Q4 2013

Complete clinical trial on Min technology: Q4 2014-Q2 2015

Q1= OCT NOV DEC

Q2= JAN FEB MAR

Q3= APR MAY JUN

Q4= JUL AUG SEP

BMSN IS RIGHT ON SCHEDULE!! THIS EXPLAINS WHY THE PPS MOVED UP SO SUDDENLY IN JUNE! THIS IS A MAJOR CATLYST!! SECURE YOUR POSITIONS AND ENJOY THE RIDE

NORTH!!

8-K for BMSN (Gene Slilencing Cancer Technology)

On May 1, 2013 Dr. Wei Ping Min ("Min") entered into an agreement ("Agreement") whereby Min assigned to Regen BioPharma Inc. ("Regen") , a wholly owned

subsidiary of Bio-Matrix Scientific Group, Inc.("the Company") , all right, title and interest in US Patent # 8,389,708 as well as all Patent

applications from the same family corresponding to numbers PCT/CA2006/000984, CA2612200 and EP1898936.("Min IP")

http://biz.yahoo.com/e/130612/bmsn8-k.html

Some people here are forgetting about BMSN Business Model! There ultimate end goal is to sell the biotechnology off to Big Pharma! Even though there

business approach is to see a product through Phase 1 & 2 before this happens, this “sale can come at any time!” The more Koos works on the development

of these technologies such as HemaXellerate and the MIN breast cancer vaccine, the more attractive and promising it becomes to big Pharma! As investors

I wouldn't worry about funding because that can come at any moment!

OUR BUSINESS MODEL | REGEN BIOPHARMA, INC.

The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II

clinical trials), followed by exit. The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition

of undervalued assets that have demonstrated proof of concept, and forming companies around these assets. Having assembled a core infrastructure

specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years

grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma.

http://www.regenbiopharma.com/business-model.html

Davis Koos now controls all three entities: Bio-Matrix Scientific Group, Regen BioPharma, Entest BioMedical according to recent developments announced

in the 8-k release! [i]Merging these entities is only logical from a business stand point! [/i]

http://biz.yahoo.com/e/130531/bmsn8-k.html

BMSN has thus far stayed current with their filings and business timeline! Keep in mind investors that these future event are guides! Anything can

happen especially with the FDA at any given notice! Expect a sudden rise in PPS with no reason before that news hits the wire! Given 4 straight weeks of

a down trend BMSN is ready to burst out like a soda bottle being shaking up will all the wacky selling pressure! It will run hard and many will chase

the PPS fast with [b]900%[/b] plus gains! I don't know any investor or trader that likes chasing unless your the savvy one that has been accumulation

during the shouts of doom and gloom ; Sky is falling messages! This is obviously the bottom! I was hoping to get some in the .001s but that [b]will

never happen[/b]! The stock after weeks of churning has now become [b]BULLISH![/b] Mark this post BMSN will run hard!

http://www.americanbulls.com/SignalPage.aspx?...icker=BMSN

I'm very happy with my position! The real question to all the newbies, Are you satified with your share count when this reaches [b].05+[/b]

Last Major PR was featured on NBC website! When FDA news hits the wire it will be covered by everyone!

http://www.nbcnews.com/id/51786808#.UZFZQIy9KSM

[b]PSTI[/b] received orphan drug designation for aplastic anemia which is the same disease HemaXellerate is treating! Its only in due time before

HemaXellerate receives orphan drug designation!

http://regulatoryaffairs.pharmaceutical-busin...tus-220213

Look at the share price the CEO purchased at!! You don't have to worry about shares being dumped on investors with no agenda other than going into a

CEOs pocket, no employees, 1 trillion shares and no agenda!! BMSN is nothing like that! Its the real deal! Most of the shares purchased by the CEOs were

brought well over .50!! Have no worries investors!

http://www.openinsider.com/search?q=bmsn

[i]The key is to be patient and accumulate! That's how the PPS bounced to almost .02 in such a short time! Change your trading strategy on this one!

Everyone need to be on accord here! Unless you like chasing! To each his own...Happy Trading! GLTA!

RIVULET MEDIA INC. (RIVU) Stock Research Links

RIVU Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

First Industrial Declares Regular Dividend Amid Growth Insights

Updated Category News Views 75

Dividend Declaration Reflects Confidence First Industrial Realty Trust, folks, just put another office stamp on their ongoing reliability quest—and I'm talking dividends. They're shelling out a tidy $0.50 per share for Q4 2026, with stockholders due to see the cash on January 19, 2027. That's like clockwork precision, showing a steadiness in what some call the unruly...

Continue Reading
Trimble's Q3 2026: Guidance Update and Record ARR

Updated Category News Views 48

Trimble Smashes Through Q3 Expectations Trimble Inc. (NASDAQ:TRMB) tossed a bit of a curveball by posting Q3 2026 results that sailed past analyst forecasts. We’re talking revenue swelling to $966.8 million, a decent 7% bump from the previous year. Now, for a company riding its 'Connect & Scale' strategy, this serves as a validation of its aggressive scaling ambitions....

Continue Reading
Fractal Sees Explosive Q2 Gain: Revenue Hits $100M

Updated Category News Views 93

Fractal’s Revenue Moment: Climbing New Peaks Fractal Analytics just knocked it out of the park, folks. Imagine this—an AI company pulling in $100 million for the first quarter, getting a 20% jump in revenue year on year. That's right, these numbers aren't just fancy figures; they're staggering proof that Fractal's hitting its AI stride. The healthcare and life...

Continue Reading
Zuellig Pharma Expands Clinical Capabilities in China

Updated Category News Views 86

Zuellig Pharma's Strategic Leap in Hangzhou You know, in the ever-evolving world of biotech and pharmaceuticals, setting up shop in the right locale can mean the difference between breakthroughs and breakdowns. So Zuellig Pharma—a major player, but not exactly a household ticker—made a smart move acquiring a clinical facility in Hangzhou. This is no minor shuffle;...

Continue Reading
Natixis' $100M Student Challenge Mixes Real Stakes

Updated Category News Views 56

Opportunity Knocks for Budding Portfolio Managers Picture this: You're a student, neck-deep in textbooks and theories, and then bam! You're handed the keys to manage a $100 million portfolio. That's the real-deal opportunity Natixis Investment Managers is dangling with its seventh Students Challenge. Diving Into the Nuts and Bolts Listen up, kids. Applications are open...

Continue Reading
VAB's Pharma Ad Guide: Emerging Trends and Insights

Updated Category News Views 191

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Continue Reading
Coretek Joins CRN's Elite AI Innovators of 2026

Updated Category News Views 69

Coretek's Leap to AI Innovator Status Here we are, folks. Another announcement hits the wires that showcases a company's ascent amid the swelling AI tide. Coretek, hailing from Farmington Hills, managed to snag a spot on CRN's inaugural 2026 AI Innovators list. No small potatoes, if you ask me, considering the competition on this playing field. Why the fuss? It's about...

Continue Reading
Allego Dominates 2026 Gartner Magic Quadrant: Why It Matters

Updated Category News Views 40

Allego Secures Top Spot Yet Again I've seen companies rise and fall on the whims of industry recognition, and let me tell ya, Allego's riding high on the right wave. For the second year running, this outfit's been named a Leader in the 2026 Gartner Magic Quadrant for Revenue Enablement Platforms. Recognized for its Completeness of Vision—yeah, that's no small feat...

Continue Reading
KOVE's Bold Lineup Expansion at EICMA 2026

Updated Category News Views 112

What's Roaring: The Latest from KOVE Anybody who’s been following motorcycle trends knows that EICMA 2026 was destined to be a spectacle, and KOVE didn’t disappoint. They rolled out a fleet of five new models, including the 125 RALLY, 350 RALLY, 650RR, and two head-turners on the electric front: the BONIC and the E-500RR. Each model brings something fresh to the...

Continue Reading
Askey & Icom Team Up: Trading Airwaves for Partnerships

Updated Category News Views 6

Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...

Continue Reading

Top 5 Most Recently Viewed Articles

Tesla's Earnings Impact: A Preview for Investors Ahead

Updated Category News Views 206

Tesla's Earnings and Market Dynamics As we gear up for Tesla's earnings announcement, all eyes are turning to the electric vehicle giant (NASDAQ: TSLA). Tesla is leading the charge as the first among the prominent group of tech companies known as the "Magnificent Seven" to reveal its financial performance. The anticipation builds as markets reflect on how business...

Continue Reading
Atos Group Releases Detailed Half-Year Financial Report for 2025

Updated Category News Views 222

Atos Group Updates on Financial Performance for 2025 Availability of the 2025 Half-year Financial Report Atos Group has made significant strides in its financial reporting for 2025, announcing the release of its half-year financial report. This document was published on the Atos website and was also filed with the French Financial Markets Authority (AMF). Insights from...

Continue Reading
Anywhere Real Estate and Canva Team Up for Agents' Success

Updated Category News Views 204

Anywhere Real Estate's Exciting New Partnership Anywhere Real Estate Inc. (NYSE: HOUS), a global frontrunner in the residential real estate sector, has recently unveiled an impactful collaboration with Canva, a recognized visual communication platform. This agreement aims to empower Every agent within their extensive network. Enhanced Tools for Affiliated Agents This...

Continue Reading
THEON Showcases Innovative A.R.M.E.D. Ecosystem at IDEX 2025

Updated Category News Views 279

THEON Unveils Revolutionary A.R.M.E.D. Ecosystem At IDEX 2025, THEON made a significant impact by showcasing its A.R.M.E.D. (Augmented Reality Modular Ecosystem of Devices), designed to elevate the capabilities of tomorrow's soldiers. This integrated solution promises to improve tactical awareness, effectiveness, and survivability for modern combat operatives....

Continue Reading
Exploring Advances in Arthrogryposis at Montreal Symposium

Updated Category News Views 304

4th International Symposium on Arthrogryposis Unveiled in Montreal MONTREAL — The Shriners Hospitals for Children - Canada is set to host the much-anticipated 4th International Symposium on Arthrogryposis from September 28 to October 1. This initiative brings together renowned healthcare professionals and researchers from various pediatric centers in Montreal,...

Continue Reading